抗体介导的排斥反应:一场艰苦的战斗

Chineae Journal of Organ Transplantation Pub Date : 2019-08-20 DOI:10.3760/CMA.J.ISSN.0254-1785.2019.08.001

Changxi Wang

{"title":"抗体介导的排斥反应:一场艰苦的战斗","authors":"Changxi Wang","doi":"10.3760/CMA.J.ISSN.0254-1785.2019.08.001","DOIUrl":null,"url":null,"abstract":"抗体介导的排斥反应(AMR)是影响移植肾远期存活的重要疾病，其发病机理较明确但疾病异质性高，临床表型多，尚缺乏有效的治疗手段，特别是迟发或慢性AMR。细化AMR分型有助于实施针对性治疗和预估疗效。病理诊断标准和抗体检测技术有待进一步优化，分子病理和无创监测(如供者游离DNA)能辅助提高AMR的诊断和治疗。基于HLA Eplets错配建立免疫风险分层有助于指导个体化免疫抑制方案，降低新生供者特异性抗体(DSA)风险。","PeriodicalId":9885,"journal":{"name":"Chineae Journal of Organ Transplantation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antibody mediated rejections: fighting an uphill battle\",\"authors\":\"Changxi Wang\",\"doi\":\"10.3760/CMA.J.ISSN.0254-1785.2019.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"抗体介导的排斥反应(AMR)是影响移植肾远期存活的重要疾病，其发病机理较明确但疾病异质性高，临床表型多，尚缺乏有效的治疗手段，特别是迟发或慢性AMR。细化AMR分型有助于实施针对性治疗和预估疗效。病理诊断标准和抗体检测技术有待进一步优化，分子病理和无创监测(如供者游离DNA)能辅助提高AMR的诊断和治疗。基于HLA Eplets错配建立免疫风险分层有助于指导个体化免疫抑制方案，降低新生供者特异性抗体(DSA)风险。\",\"PeriodicalId\":9885,\"journal\":{\"name\":\"Chineae Journal of Organ Transplantation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chineae Journal of Organ Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.0254-1785.2019.08.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chineae Journal of Organ Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.0254-1785.2019.08.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

抗体介导的排斥反应(AMR)是影响移植肾远期存活的重要疾病，其发病机理较明确但疾病异质性高，临床表型多，尚缺乏有效的治疗手段，特别是迟发或慢性AMR。细化AMR分型有助于实施针对性治疗和预估疗效。病理诊断标准和抗体检测技术有待进一步优化，分子病理和无创监测(如供者游离DNA)能辅助提高AMR的诊断和治疗。基于HLA Eplets错配建立免疫风险分层有助于指导个体化免疫抑制方案，降低新生供者特异性抗体(DSA)风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文